← Leaderboards
Carl Peter Blobel
Hospital For Special Surgery
$11,559,576
Attributed
$11,559,576
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $915.8K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,559,576 · 5
By mechanism
R01$9,580,552 · 3
R35$1,969,024 · 1
R13$10,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMetalloproteasesCellsRegulationEpidermal Growth Factor ReceptorLigandsSignal TransductionDisintegrinsMembraneStructureIn VivoSignal PathwayPathway InteractionsReceptor Protein-Tyrosine KinasesCytoplasmic TailAffectGeneticBaseMolecularProteinsMutantCancer TherapyBiochemicalTnf Gene
Grant awards (38)
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling$411,392
R35 · FY2024 · GM · contact PI
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling$411,392
R35 · FY2023 · GM · contact PI
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling$411,392
R35 · FY2022 · GM · contact PI
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling$411,392
R35 · FY2021 · GM · contact PI
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling$323,456
R35 · FY2020 · GM · contact PI
iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling$376,200
R01 · FY2019 · GM · contact PI
iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling$376,200
R01 · FY2018 · GM · contact PI
iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling$360,369
R01 · FY2018 · GM · contact PI
iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling$376,200
R01 · FY2017 · GM · contact PI
iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling$376,200
R01 · FY2016 · GM · contact PI
ADAMs: Key Regulators of EGFR Signaling$117,334
R01 · FY2015 · GM · contact PI
ADAMs: Key Regulators of EGFR Signaling$351,000
R01 · FY2014 · GM · contact PI
ADAMs: Key Regulators of EGFR Signaling$338,715
R01 · FY2013 · GM · contact PI
ADAMs: Key Regulators of EGFR Signaling$351,000
R01 · FY2012 · GM · contact PI
ADAMs: Key Regulators of EGFR Signaling$351,000
R01 · FY2011 · GM · contact PI
ADAMs: Key regulators of EGFR signaling$311,982
R01 · FY2009 · GM · contact PI
ADAMs: Key regulators of EGFR signaling$297,500
R01 · FY2009 · GM · contact PI
Role of ADAMs 9 and 15 in Proliferative Retinopathy$69,431
R01 · FY2009 · EY · contact PI
Matrix Metalloproteinases Gordon Conference$5,000
R13 · FY2009 · CA · contact PI
Role of ADAMs 9 and 15 in Proliferative Retinopathy$404,435
R01 · FY2008 · EY · contact PI
ADAMs: Key regulators of EGFR signaling$311,982
R01 · FY2008 · GM · contact PI
Role of ADAMs 9 and 15 in Proliferative Retinopathy$513,801
R01 · FY2007 · EY · contact PI
ADAMs: Key regulators of EGFR signaling$311,982
R01 · FY2007 · GM · contact PI
Matrix Metalloproteinases Gordon Conference$5,000
R13 · FY2007 · CA · contact PI
Role of ADAMs 9 and 15 in Proliferative Retinopathy$513,692
R01 · FY2006 · EY · contact PI
ADAMs: Key regulators of EGFR signaling$321,300
R01 · FY2006 · GM · contact PI
Role of ADAMs 9 and 15 in Proliferative Retinopathy$523,080
R01 · FY2005 · EY
Functional and biochemical studies of ADAM19$297,500
R01 · FY2005 · GM
Role of ADAMs 9 and 15 in Proliferative Retinopathy$95,200
R01 · FY2005 · EY
Role of ADAMs 9 and 15 in Proliferative Retinopathy$376,859
R01 · FY2004 · EY
Functional and biochemical studies of ADAM19$255,662
R01 · FY2004 · GM
Role of ADAMs 9 and 15 in Proliferative Retinopathy$51,390
R01 · FY2004 · EY
Functional and biochemical studies of ADAM19$23,288
R01 · FY2004 · GM
Functional and biochemical studies of ADAM19$277,375
R01 · FY2003 · GM
METALLOPROTEASE DISINTEGRIN MDC9$334,968
R01 · FY2002 · GM
Functional and biochemical studies of ADAM19$273,685
R01 · FY2002 · GM
METALLOPROTEASE DISINTEGRIN MDC9$325,303
R01 · FY2001 · GM
METALLOPROTEASE DISINTEGRIN MDC9$315,919
R01 · FY2000 · GM